Skip to main content

Advertisement

Table 3 Univariate and multivariate analysis of factors affecting overall survival of patients with advanced hepatobiliary cancers (n = 80)

From: Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study

Variables Values Univariate   Multivariate  
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Clinicopathological factors
 Age (years) < 65 vs. ≥65 1.45 (0.91–2.33) 0.121 0.96 (0.56–1.65) 0.880
 Gender Male vs. Female 1.51 (0.93–2.45) 0.096 1.55 (0.86–2.78) 0.144
 ECOG-PS 0–1 vs. 2 2.67 (1.44–4.92) 0.002 2.61 (1.26–5.44) 0.010
 BMI (kg/m2) < 23 vs. ≥23 0.70 (0.44–1.11) 0.127   
 Tumor Type HCC vs. BTC or cHCC-CC 2.50 (1.49–4.19) 0.001 2.18 (1.15–4.15) 0.018
 Previous anticancer therapy Yes vs. No 1.77 (1.08–2.89) 0.023 1.01 (0.53–1.90) 0.980
  Prior surgery Yes vs. No 0.77 (0.49–1.21) 0.250   
  Prior chemotherapy No vs. Yes 1.31 (0.82–2.08) 0.260   
  Prior radiotherapy No vs. Yes 1.12 (0.62–2.00) 0.710   
Biochemical factors
 Ferritin (ng/mL) Lowa vs. Highb 2.47 (1.54–3.96) < 0.001 1.96 (1.03–3.73) 0.041
 Hb (g/dL) Highc vs. Lowd 2.24 (1.35–3.73) 0.002 1.50 (0.81–2.79) 0.200
 Total bilirubin (mg/dL) ≤1.2 vs. > 1.2 2.44 (1.37–4.35) 0.002 2.02 (1.00–4.07) 0.051
 AST (IU/L) < 40 vs. ≥40 1.56 (0.99–2.47) 0.058   
 ALT (IU/L) < 40 vs. ≥40 0.85 (0.53–1.36) 0.500   
 γ-GT (IU/L) ≤66 vs. > 66 1.98 (1.20–3.25) 0.007 0.91 (0.46–1.80) 0.790
 PT INR ≤1.16 vs. > 1.16 1.33 (0.81–2.19) 0.260   
 Albumin (g/dL) ≥3.5 vs. < 3.5 2.16 (1.18–3.98) 0.013 1.64 (0.77–3.49) 0.198
 WBC (×103/μL) < 10.0 vs. ≥10.0 2.98 (1.49–5.98) 0.002 1.80 (0.79–4.11) 0.165
 CRP (mg/L) < 10.0 vs. ≥10.0 3.23 (1.99–5.25) < 0.001 2.12 (1.20–3.76) 0.010
  1. ECOG-PS Eastern cooperative oncology group performance status, BMI body mass index, Hb hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, γ-GT gamma-glutamyl transpeptidase, PT INR prothrombin time international normalized ratio, WBC white blood cell, CRP c-reactive protein, HCC hepatocellular carcinoma, BTC biliary tract cancers, cHCC-CC combined hepatocellular-cholangiocarcinoma, CI confidence interval
  2. a female≤150 male≤200, b female> 150 male> 200, c female ≥12.0 male ≥13.0, d female < 12.0 male < 13.0